BMY logo
BMY
Bristol-Myers Squibb

Debt And Patent Expiries Will Erode US Pharma Margins

Published
09 Apr 25
Updated
16 Aug 25
AnalystLowTarget's Fair Value
US$35.86
35.1% overvalued intrinsic discount
16 Aug
US$48.44
Loading
1Y
-1.9%
7D
5.4%

Author's Valuation

US$35.9

35.1% overvalued intrinsic discount

AnalystLowTarget Fair Value

Narrative
Updates3

Shared on07 May 25
Fair value Decreased 27%

Read more

Shared on30 Apr 25
Fair value Decreased 3.70%

AnalystLowTarget made no meaningful changes to valuation assumptions.

Read more

Shared on16 Apr 25
Fair value Increased 26%

AnalystLowTarget made no meaningful changes to valuation assumptions.

Read more